- 1. (-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic Acid
- [A hydrazine derivative of dopa. Carbidopa is a peripheral dopa decarboxylase inhibitor that is used as an adjunct to levodopa administration to prevent peripheral biosynthesis of levodopa to dopamine, thereby reducing peripheral side effects. Carbidopa does not penetrate the blood brain barrier so that levodopa, after it reaches the brain, can be metabolized to dopamine by dopa decarboxylase where it exerts its effect on dopamine receptors. ( NCI )] (UMLS (NCI) C0006982) =Organic Chemical; Pharmacologic Substance =[CN500] ANTIPARKINSON AGENTS;
hydrazine;
3-Hydroxy-alpha-methyl-L-tyrosine;
=CARBIDOPA 25 MG;
CARBIDOPA 50 MG;
CARBIDOPA 10 MG;
Carbidopa 12.5 MG / entacapone 200 MG / Levodopa 50 MG Oral Tablet;
CARBIDOPA 37.5 MG;
| - 51. L-Valine, N-(1-oxopentyl)-N-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-
- [An orally active nonpeptide triazole-derived antagonist of angiotensin (AT) II with antihypertensive properties. Valsartan selectively and competitively blocks the binding of angiotensin II to the AT1 subtype receptor in vascular smooth muscle and the adrenal gland, preventing AT II-mediated vasoconstriction, aldosterone synthesis and secretion, and renal reabsorption of sodium, and resulting in vasodilation, increased excretion of sodium and water, a reduction in plasma volume, and a reduction in blood pressure. ( NCI )] (UMLS (NCI) C0216784) =Organic Chemical; Pharmacologic Substance ;
=Tetrazoles;
valine;
[CV805] ANGIOTENSIN II INHIBITORS;
=VALSARTAN 160 MG;
VALSARTAN 80 MG;
VALSARTAN 40 MG;
VALSARTAN 320 MG;
|
- 2. (Laparoscopic) adjustment of size of adjustable gastric restrictive device
- [ ] (UMLS (ICD9CM) C1456111) ADJUST GAST RESTRICT DEV;
=Therapeutic or Preventive Procedure | - 52. L/min
- [A metric unit of volumetric flow rate defined as the rate at which one liter of matter crosses a given surface during the period of time equal to one minute. ( NCI )] (UMLS (NCI) C0439393) =Quantitative Concept
|
- 3. *Length Increment
- (UMLS (HL7) C1547029) =Quantitative Concept =Kind of quantity;
| - 53. L/s
- [A metric unit of volumetric flow rate defined as the rate at which one liter of matter crosses a given surface during the period of time equal to one second. ( NCI )] (UMLS (NCI) C0439394) =Quantitative Concept
|
- 4. *Liquefaction
- (UMLS (HL7) C1547030) =Quantitative Concept =Kind of quantity;
| - 54. L0
- [No evidence of lymphatic vessel invasion, in accordance with TNM classification system guidelines. (from AJCC 6th Ed.) ( NCI )] (UMLS (NCI) C0441917) =Finding
|
- 5. 125-L-Serine-2-133-interleukin 2
- [A laboratory-made colony-stimulating factor that stimulates the production of blood cells, especially platelets, during chemotherapy. It is a cytokine that belongs to the family of drugs called hematopoietic (blood-forming) agents. Also called interleukin-2 or IL-2. ( NCI )] (UMLS (NCI) C0218986) =Amino Acid, Peptide, or Protein; Pharmacologic Substance ;
=[IM700] IMMUNE STIMULANTS;
Recombinant Protein =ALDESLEUKIN 22 MILLION UNT/VIL | - 55. L1
- (UMLS (NCI) C0441918) =Finding
|
- 6. 15-Lipoxygenase, Reticulocyte Arachidonate
- [Encoded by human ALOX15 Gene, a putative mutator gene regulated by tumor-suppressor TP53, 661-amino acid 74.7 kD cytoplasmic Arachidonate 15-Lipoxygenase (Lipoxygenase Family) acts in leukotriene biosynthesis and is implicated in anti-inflammation, membrane remodeling, and cancer development or metastasis. It converts arachidonic acid to 15s-hydroperoxyeicosatetraenoic acid. (OMIM, Swiss-Prot, and NCI) ( NCI )] (UMLS (NCI) C0003692) =Amino Acid, Peptide, or Protein; Enzyme
| - 56. L1 Adult Acute Lymphoblastic Leukemia
- (UMLS (NCI) C0279589) =Neoplastic Process
|
- 7. 177 Lu-CC49
- [A radioimmunoconjugate of the humanized monoclonal antibody (MoAB) CC49 labeled with lutetium 131 (Lu-177). MoAb CC49 binds to the pancarcinoma tumor-associated glycoprotein (TAG)-72 with high affinity. Lu-177 MoAb CC49 delivers gamma radiation emitting Lu-177 nuclide directly to tumor cells that express TAG-72, thereby may be used in radioimmunotherapeutic treatment of cancers. ( NCI )] (UMLS (NCI) C0935675) Lutetium Lu 177 Monoclonal Antibody CC49;
=Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor | - 57. L1 Vertebra
- (UMLS (NCI) C0223492) =Body Part, Organ, or Organ Component
|
- 8. 2 lysophosphatidylcholine acylhydrolase
- [An enzyme that catalyzes the hydrolysis of a single fatty acid ester bond in lysoglycerophosphatidates with the formation of glyceryl phosphatidates and a fatty acid. EC 3.1.1.5. ( MSH )] (UMLS (CSP) C0024361) =Amino Acid, Peptide, or Protein; Enzyme ;
=carboxylesterase;
| - 58. L2 Vertebra
- (UMLS (NCI) C0223507) =Body Part, Organ, or Organ Component
|
- 9. 23-L-Leucinecolony-Stimulating Factor 2
- [A colony-stimulating factor that stimulates the production of white blood cells, especially granulocytes and macrophages, and cells (in the bone marrow) that are precursors of platelets. It is a cytokine that belongs to the family of drugs called hematopoietic (blood-forming) agents. Also called granulocyte-macrophage colony-stimulating factor (GM-CSF). ( NCI )] (UMLS (NCI) C0216231) =Amino Acid, Peptide, or Protein; Pharmacologic Substance ;
=Colony-Stimulating Factor, Granulocyte-Macrophage;
[BL400] BLOOD FORMATION PRODUCTS =sargramostim 0.5 MG/ML;
SARGRAMOSTIM 500 MCG;
SARGRAMOSTIM 250 MCG | - 59. L3 Vertebra
- (UMLS (NCI) C0223522) =Body Part, Organ, or Organ Component
|
- 10. 29-L-Argininamide-30-de-L-glutamine-31-de-L-glutamine-32-deglycine-33-de-L-glutamic acid-34-de-L-serine-35-de-L-asparagine-36-de-L-glutamine-37-de-L-glutamic acid-38-de-L-arginine-39-deglycine-40-de-L-alanine-41-de-L-arginine-42-de-L-alanine-43-de-L-argin
- [The acetate salt form of sermorelin, a synthetic, amidated 29-amino acid peptide that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing hormone (GHRH). Sermorelin acetate directly stimulates the pituitary gland, resulting in release of growth hormone leading to increased plasma growth hormone, which is responsible for many biological processes and counteracts growth hormone deficiency. ( NCI )] (UMLS (NCI) C0162725) =Amino Acid, Peptide, or Protein; Pharmacologic Substance ;
=GHRH;
=SERMORELIN ACETATE 50 MCG;
SERMORELIN ACETATE 1 MG;
SERMORELIN ACETATE 0.5 MG | - 60. L4 Vertebra
- (UMLS (NCI) C0223537) =Body Part, Organ, or Organ Component
|
- 11. APETITU GALTZEA(ESKL. T06)
- (UMLS (ICPC) C1971624) (Loss of appetite; APETITU GALTZEA(ESKL. T06); Nedsat appetit; Verminderde eetlust; RUOKAHALUTTOMUUS; Perte d'appetit; Appetitlosigkeit; ibud teavon; etvagytalansag; Perdita di appetito; NEDSATT MATLYST; Perca de apetite; Perdida del apetito; APTITLOSHET) Appetitlosigkeit; APTITLOSHET; etvagytalansag; ibud teavon; Loss of appetite; Nedsat appetit; NEDSATT MATLYST; Perca de apetite; Perdida del apetito; Perdita di appetito; Perte d'appetit; =Finding ;
=ENDOCRINE, METABOLIC AND NUTRITIONAL; Symptoms and Complaints Component | - 61. L5 Vertebra
- (UMLS (NCI) C0223552) =Body Part, Organ, or Organ Component
|
- 12. L
- [Mandibular left first primary molar ( HL7V3.0 )] (UMLS (HL7) C0227103) =Body Part, Organ, or Organ Component =Primary dentition;
| - 62. L6
- [The protein is a member of the transmembrane 4 superfamily, also known as the tetraspanin family. Most of these members are cell-surface proteins that are characterized by the presence of four hydrophobic domains. The proteins mediate signal transduction events that play a role in the regulation of cell development, activation, growth and motility. This encoded protein is a cell surface antigen and is highly expressed in different carcinomas. (from LocusLink) ( NCI )] (UMLS (NCI) C0167206) =Amino Acid, Peptide, or Protein; Immunologic Factor ;
|
- 13. L 694,458
- [ ] (UMLS (CSP) C0950972) =Organic Chemical; Pharmacologic Substance
| - 63. L6
- [A murine IgG2a monoclonal antibody with potential antineoplastic activity. Monoclonal antibody L6 binds to the L6 antigen, a cell surface glycoprotein overexpressed in many carcinomas, and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against L6-expressing tumor cells. This agent may be conjugated with various toxins in order to target their cytotoxic activity to tumor cells expressing the L6 antigen. (NCI04) ( NCI )] (UMLS (NCI) C0281019) =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor
|
- 14. L 705,126
- (UMLS (NCI) C0297632) =Organic Chemical; Pharmacologic Substance
| - 64. L651582
- (UMLS (NCI) C0286394) =Organic Chemical; Pharmacologic Substance
|
- 15. L 735524
- [ ] (UMLS (CSP) C0701104) =Organic Chemical; Pharmacologic Substance ;
| - 65. LA
- [A country in Southeastern Asia, northeast of Thailand, west of Vietnam. (NCI) ( NCI )] (UMLS (NCI) C0023034) =Geographic Area ◊ [A state in the southern midwest United States. Its capital is Baton Rouge. ( NCI )] (UMLS (NCI) C0024024) Geographic Area
|
- 16. L 778,123
- [An anticancer drug that belongs to the family of drugs called enzyme inhibitors. It may inhibit the transformation of normal cells into cancer cells. ( NCI )] (UMLS (NCI) C0796327) L-778,123;
L-778123 =Organic Chemical; Pharmacologic Substance ;
| - 66. La Crosse virus
- [A serotype of the species California encephalitis virus (ENCEPHALITIS VIRUS, CALIFORNIA), in the genus ORTHOBUNYAVIRUS, causing human MENINGOENCEPHALITIS. This is the agent most responsible for California encephalitis (ENCEPHALITIS, CALIFORNIA), the most prevalent mosquito-borne disease recognized in the United States. ( MSH )] (UMLS (CSP) C0022858) =Virus ;
|
- 17. L cell
- [cells from c3h mouse fibroblasts grown in tissue culture that can support replication of many types of viruses. ( CSP )] (UMLS (CSP) C0022827) =Cell ;
=cell line;
neoplastic cell | - 67. La element
- [rare metallic element, symbol La, atomic number 57. ( CSP )] (UMLS (CSP) C0023031) =Element, Ion, or Isotope =Metals, Rare Earth;
|
- 18. L form bacteria
- [ ] (UMLS (CSP) C0597958) =Bacterium ;
| - 68. La Jolla Band of Luiseno Mission Indians of the La
- (UMLS (HL7) C1554349) =Population Group =NativeEntityContiguous;
|
- 19. L iditol dehydrogenase
- [An alcohol oxidoreductase which catalyzes the oxidation of L-iditol to L-sorbose in the presence of NAD. It also acts on D-glucitol to form D-fructose. It also acts on other closely related sugar alcohols to form the corresponding sugar. EC 1.1.1.14 ( MSH )] (UMLS (CSP) C0020809) =Amino Acid, Peptide, or Protein; Enzyme ;
=alcohol oxidoreductase;
| - 69. La Posta Band of Diegueno Mission Indians of the L
- (UMLS (HL7) C1554350) =Population Group =NativeEntityContiguous;
|
- 20. L iduronate
- [ ] (UMLS (CSP) C0178445) =Carbohydrate; Biologically Active Substance
| - 70. La Raza
- (UMLS (HL7) C1553369) =Population Group =Mexican;
|
- 21. L iduronidase
- [An enzyme that hydrolyzes iduronosidic linkages in desulfated dermatan. Deficiency of this enzyme produces Hurler's syndrome. EC 3.2.1.76. ( MSH )] (UMLS (CSP) C0020818) =Amino Acid, Peptide, or Protein; Enzyme ;
| - 71. Lab
- [A workplace for the conduct of scientific research. ( NCI )] (UMLS (NCI) C0022877) =Manufactured Object; Organization
|
- 22. L NMMA
- [An amino acid derivative used to counteract high blood pressure caused by interleukin-2. ( NCI )] (UMLS (CSP) C0069477) =Amino Acid, Peptide, or Protein; Biologically Active Substance ;
| - 72. Lab
- [The Labrador Retriever is a solid, muscular dog, with a short, hard, water-resistant double coat that does not have any waves. It comes in solid black, yellow, or chocolate. There is also said to be a rare silver or gray color. The medium-sized ears are pendant. The webbed feet aid in swimming. Height: 21-24 inches (53-61 cm.) Weight: 55-75 pounds (25-34kg.) ( NCI )] (UMLS (NCI) C0324431) =Mammal
|
- 23. L selectin
- [L-Selectin is a cell surface glycoprotein adhesion molecule that serves as a homing receptor for lymphocytes to lymph node high endothelial venules. The molecule is composed of multiple domains: one homologous to lectins, one to epidermal growth factor, and two to C3/C4 binding protein consensus repeat units. L-Selectin may also play a role in neutrophil adhesion to endothelium at sites of inflammation. A tissue-specific mucin-like endothelial glycoprotein appears to function as ligand for L-selectin, in the role of scaffold that presents carbohydrates to the L-selectin lectin domain. PLAUR is directly associated with the carbohydrate-binding domain of L-selectin in the membrane of neutrophils, an association analogous to that between PLAUR and beta-2 integrins. (from OMIM 153240 and NCI) ( NCI )] (UMLS (CSP) C0125090) =Amino Acid, Peptide, or Protein; Immunologic Factor; Receptor
| - 73. Lab Alert
- [Proposed therapy may be inappropriate or contraindicated due to recent lab test results ( HL7V3.0 )] (UMLS (HL7) C1553536) =Intellectual Product =Observation Alert;
|
- 24. L-12717
- (UMLS (NCI) C0124796) =Organic Chemical; Pharmacologic Substance ;
| - 74. Lab Findings
- [The result of a lab test to measure an attribute or to determine the presence, absence or degree of a condition. ( NCI )] (UMLS (NCI) C0237076) =Laboratory or Test Result ;
|
- 25. L-3-(3,4-Dihydroxyphenyl)-2-methylalanine Ethyl Ester Hydrochloride
- [The hydrochloride salt form of methyldopa, a phenylalanine derivate and aromatic amino acid decarboxylase inhibitor with antihypertensive activity. Methyldopa is a prodrug and is metabolized in the central nervous system. The antihypertensive action of methyldopa seems to be attributable to its conversion into alpha-methylnorepinephrine, which is a potent alpha-2 adrenergic agonist that binds to and stimulates potent central inhibitory alpha-2 adrenergic receptors. This results in a decrease in sympathetic outflow and decreased blood pressure. ( NCI )] (UMLS (NCI) C0304527) =Organic Chemical; Pharmacologic Substance =METHYLDOPATE;
=METHYLDOPATE HYDROCHLORIDE 50 MG/ML | - 75. Lab Tech
- [A technically trained person who performs laboratory activities and provides laboratory analysis according to laboratory policies, procedures and protocols. ( NCI )] (UMLS (NCI) C1270980) Laboratory Technologist;
=Professional or Occupational Group |
- 26. L-377,202
- [A substance that is being studied in the treatment of cancer. ( NCI )] (UMLS (NCI) C0879383) L-377202;
=Organic Chemical; Pharmacologic Substance ;
| - 76. lab test category
- [ Definition: ( HL7V3.0 )] (UMLS (HL7) C1699174) =Intellectual Product =ActCode;
|
- 27. L-5103
- (UMLS (NCI) C0733661) =Organic Chemical; Antibiotic ;
| - 77. Lab to obtain specimen from patient
- (UMLS (HL7) C1546521) =Intellectual Product =Specimen Action Code;
|
- 28. L-744,832
- [A farnesyl transferase inhibitors. ( NCI )] (UMLS (NCI) C0384181) =Amino Acid, Peptide, or Protein; Pharmacologic Substance ;
| - 78. Label
- [A brief description given for purposes of identification; an identifying or descriptive marker that is attached to an object. ( NCI )] (UMLS (NCI) C0181496) =Manufactured Object
|
- 29. L-754030
- (UMLS (NCI) C0759820) =Organic Chemical; Pharmacologic Substance ;
| - 79. Labeling
- (UMLS (HL7) C1548779) =Qualitative Concept =Specimen Reject Reason;
|
- 30. L-778,123/Paclitaxel
- (UMLS (NCI) C0879293) =Therapeutic or Preventive Procedure
| - 80. LABETALOL
- [A third generation selective alpha-1-adrenergic antagonist and non-selective beta-adrenergic antagonist with vasodilatory and antihypertensive properties. Labetalol competitively binds to alpha-1-adrenergic receptors in vascular smooth muscle, thereby inhibiting the adrenergic stimulation of endothelial cell function and vasoconstriction in peripheral blood vessels. This agent also binds to beta-receptors in the bronchial and vascular smooth muscle, resulting in a decrease in adrenergic stimulation. The result is a decrease in resting and exercise heart rates, cardiac output, and in both systolic and diastolic blood pressure, thereby resulting in vasodilation, and negative chronotropic and inotropic cardiac effects. ( NCI )] (UMLS (NCI) C0022860) =Organic Chemical; Pharmacologic Substance =Ethanolamines;
[CV100] BETA-BLOCKERS/RELATED =Labetalol Hydrochloride;
|
- 31. L-791456
- (UMLS (NCI) C1097007) =Organic Chemical; Pharmacologic Substance ;
| - 81. Labetalol Hydrochloride
- [The hydrochloride form of labetalol, a third generation selective alpha-1-adrenergic antagonist and non-selective beta-adrenergic antagonist with vasodilatory and antihypertensive properties. Labetalol competitively binds to alpha-1-adrenergic receptors in vascular smooth muscle, thereby inhibiting the adrenergic stimulation of endothelial cell function and vasoconstriction in peripheral blood vessels. This agent also binds to beta-receptors in the bronchial and vascular smooth muscle, resulting in a decrease in adrenergic stimulation. The result is a decrease in resting and exercise heart rates, cardiac output, and in both systolic and diastolic blood pressure, thereby resulting in vasodilation, and negative chronotropic and inotropic cardiac effects. ( NCI )] (UMLS (NCI) C0699440) =Organic Chemical; Pharmacologic Substance =LABETALOL;
=LABETALOL HYDROCHLORIDE 100 MG;
LABETALOL HYDROCHLORIDE 200 MG;
LABETALOL HYDROCHLORIDE 300 MG;
LABETALOL HYDROCHLORIDE 5 MG/ML;
|
- 32. L-Asnase
- (UMLS (NCI) C1510952) =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Enzyme
| - 82. Labia
- (UMLS (HL7) C0227759) =Body Part, Organ, or Organ Component =Body Part;
|
- 33. L-Cell Glucagon-Like Peptide Producing Neoplasm
- (UMLS (NCI) C1334328) L-Cell Glucagon-Like Peptide Producing Tumor =Neoplastic Process ;
| - 83. Labia Majora
- (UMLS (HL7) C0227760) =Body Part, Organ, or Organ Component =Body Part;
|
- 34. l-Deprenyl
- [A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual, 1994, p385) The compound without isomeric designation is Deprenyl. ( MSH )] (UMLS (NCI) C0036579) =Organic Chemical; Pharmacologic Substance ;
=[CN500] ANTIPARKINSON AGENTS;
Phenethylamines =(-)-Phenylisopropylmethylpropynylamine;
| - 84. Labia Minora
- (UMLS (HL7) C0227766) =Body Part, Organ, or Organ Component =Body Part;
|
- 35. L-Glutamic Acid, N-(4-(2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)
- [A synthetic pyrimidine-based antifolate. Pemetrexed binds to and inhibits the enzyme thymidylate synthase (TS), which catalyses the methylation of 2'-deoxyuridine-5'-monophosphate (dUMP) to 2'-deoxythymidine-5'-monophosphate (dTMP), an essential precursor in DNA synthesis. ( NCI )] (UMLS (NCI) C0210657) =Organic Chemical; Pharmacologic Substance ;
| - 85. Labial frenectomy
- (UMLS (ICD9CM) C0191994) =Therapeutic or Preventive Procedure
|
- 36. L-Methionine
- [primary aminoacid with the side chain -CH2CH2SCH3, which, in the form of its S-adenosyl derivative (SAM), also serves as the principle methyl group donor of biosynthetic pathways. ( CSP )] (UMLS (NCI) C0025646) =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Biologically Active Substance =Amino Acids, Essential;
Amino Acids, Sulfur;
Amino Acids, Neutral;
primary aminoacid;
Inactive Ingredient Preparations;
=5'-[(3-Amino-3-carboxypropyl)methylsulfonio]-5'-deoxyadenosine Hydroxide, Inner Salt;
RACEMETHIONINE;
Butanoic acid, 2-amino-4-(methylseleno)-;
METHIONINE POWDER (GM);
CRITICARE HN LIQUID;
METHIONINE 500 MG;
METHIONINE 200 MG;
METHIONINE 0.25 GM;
METHIONINE 0.45 GM;
METHIONINE 0.6 MG/ML;
METHIONINE 0.60 MG/ML;
METHIONINE 0.73 MG/ML;
METHIONINE 0.86 MG/ML;
METHIONINE 1.2 MG/ML;
METHIONINE 1.46 MG/ML;
METHIONINE 1.72 MG/ML;
METHIONINE 1.8 MG/ML;
METHIONINE 100 MG/100ML;
METHIONINE 125 MG/100ML;
METHIONINE 13.75 MG;
METHIONINE 140 MG/100ML;
METHIONINE 160 MG;
METHIONINE 2.06 MG/ML;
METHIONINE 2.8 MG/ML;
METHIONINE 200 MG/100ML;
METHIONINE 203 MG;
METHIONINE 22 MG/GM;
METHIONINE 258 MG/100ML;
METHIONINE 280 MG;
METHIONINE 3.4 MG/ML;
METHIONINE 318 MG;
METHIONINE 318 MG/100ML;
METHIONINE 340 MG;
METHIONINE 4.5 MG;
METHIONINE 400 MG;
METHIONINE 400 MG/100ML;
METHIONINE 450 MG/100ML;
METHIONINE 492 MG;
METHIONINE 492 MG/100ML;
METHIONINE 5.7 MG/ML;
METHIONINE 530 MG/100ML;
METHIONINE 7.49 MG/ML;
METHIONINE 726 MG/100ML;
METHIONINE 880 MG;
METHIONINE 25 MG | - 86. LABIAL FRENOTOMY
- (UMLS (ICD9CM) C0191966) =Therapeutic or Preventive Procedure
|
- 37. L-PAM/MePRDL
- (UMLS (NCI) C0281314) =Therapeutic or Preventive Procedure ;
| - 87. Labial Mucosa
- [The inner lining of the lips. ( NCI )] (UMLS (NCI) C0226927) =Body Part, Organ, or Organ Component
|
- 38. L-PAM/MePRDL/VCR
- (UMLS (NCI) C0279441) =Therapeutic or Preventive Procedure
| - 88. Labial Salivary Gland
- (UMLS (NCI) C0930554) =Body Part, Organ, or Organ Component
|
- 39. L-PAM/MNI
- (UMLS (NCI) C0280679) =Therapeutic or Preventive Procedure
| - 89. LaBID
- (UMLS (NCI) C0700844) =Organic Chemical; Pharmacologic Substance
|
- 40. L-PAM/PCB/VBL
- (UMLS (NCI) C0211067) =Therapeutic or Preventive Procedure
| - 90. labor
- [The repetitive uterine contraction during childbirth which is associated with the progressive dilation of the uterine cervix (CERVIX UTERI). Successful labor results in the expulsion of the FETUS and PLACENTA. Obstetric labor can be spontaneous or induced (LABOR, INDUCED). ( MSH )] (UMLS (CSP) C0022864) =Organism Function ;
|
- 41. L-PAM/PRDL
- (UMLS (NCI) C0796401) Melphalan/Prednisolone;
=Therapeutic or Preventive Procedure | - 91. Labor and Delivery
- (UMLS (HL7) C1561959) =Intellectual Product =Admission Type;
|
- 42. L-PAM/PRED
- (UMLS (NCI) C0284383) =Therapeutic or Preventive Procedure
| - 92. labor and delivery
- (UMLS (HL7) C1546400) =Idea or Concept =EncounterAdmissionSource;
|
- 43. L-PAM/PRED/VCR
- (UMLS (NCI) C0279514) =Therapeutic or Preventive Procedure
| - 93. Labor and industries number
- (UMLS (HL7) C1549707) =Idea or Concept =Identifier type;
Practitioner ID number type |
- 44. L-PAM/TAX
- (UMLS (NCI) C0281608) =Therapeutic or Preventive Procedure ;
| - 94. labor complication
- [medical problems associated with childbirth including cephalopelvic disproportion, hemorrhage, or fetal distress. ( CSP )] (UMLS (CSP) C0022865) =Disease or Syndrome ;
=Pregnancy Complication;
Pregnancy Disorder =abruptio placentae;
Dystocia;
Fetal Membranes, Premature Rupture;
Placenta Accreta;
Placenta Praevia;
ERDITZE ONDORENGO ODOLJARIO GARRANTZITSUA;
Uterine Rupture;
|
- 45. L-PAM/TNF
- (UMLS (NCI) C0281628) =Therapeutic or Preventive Procedure
| - 95. labor union
- [organization of workers formed for the purpose of serving the members' interests with respect to wages, status and working conditions. ( CSP )] (UMLS (CSP) C0022874) =Organization ;
=Job;
club |
- 46. L-PAM/TSPA
- (UMLS (NCI) C0050572) =Therapeutic or Preventive Procedure
| - 96. Laboratories
- [A room or building equipped for scientific experimentation, research, testing, or clinical studies of materials, fluids, or tissues obtained from patients. ( HL7V3.0 )] (UMLS (HL7) C1619828) =Intellectual Product ;
=NUCC Health Care Provider Taxonomy;
=Clinical Medical Laboratory;
Physiological Laboratory, (Independent Physiological Lab);
Dental Laboratory;
|
- 47. L-PAM/VCR
- (UMLS (NCI) C0280991) =Therapeutic or Preventive Procedure
| - 97. Laboratories; Clinical Medical Laboratory
- [(1) A clinical laboratory is a facility for the biological, microbiological, serological, chemical, immunohematological, hematological, biophysical, cytological, pathological, or other examination of materials derived from the human body for the purpose of providing information for the diagnosis, prevention, or treatment of any disease or impairment of, human beings. These examinations also include procedures to determine, measure, or otherwise describe the presence or absence of various substances or organisms in the body. Facilities only collecting or preparing specimens (or both) or only serving as a mailing service and not performing testing are not considered clinical laboratories. (2) Any facility that examines materials from the human body for purposes of providing information for the diagnosis, prevention, or treatment of any disease or impairment of, or the assessment of, the health of human beings. Typical divisions of a clinical laboratory include hematology, cytology, bacteriology, histology, biochemistry, medical toxicology, and serology. ( HL7V3.0 )] (UMLS (HL7) C1551301) =Manufactured Object; Health Care Related Organization =HealthcareProviderTaxonomyHIPAA;
|
- 48. L-Phenylalanine, 4-hydroxy-
- [amino acid, p-hydroxyphenylalanine, found in most proteins, synthesized metabolically from phenylalanine; a precursor of thyroid hormones, catecholamines, and melanin. ( CSP )] (UMLS (NCI) C0041485) =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Biologically Active Substance =Amino Acids, Cyclic;
hydroxyaminoacid;
primary aminoacid;
[TN503] AMINO ACIDS/PROTEINS, ORAL =Methyltyrosines;
tirofiban;
CRITICARE HN LIQUID;
TYROSINE 500 MG;
TYROSINE 0.3 MG/ML;
TYROSINE 0.33 MG/ML;
TYROSINE 0.39 MG/ML;
TYROSINE 0.40 MG/ML;
TYROSINE 0.44 MG/ML;
TYROSINE 0.94;
TYROSINE 0.94 MG/ML;
TYROSINE 1.15 MG/ML;
TYROSINE 1.35 MG/ML;
TYROSINE 1.89 MG/ML;
TYROSINE 14 MG;
TYROSINE 2.3 MG/ML;
TYROSINE 2.7 MG/ML;
TYROSINE 22 MG;
TYROSINE 22 MG/100ML;
TYROSINE 31 MG/100ML;
TYROSINE 33 MG/100ML;
TYROSINE 34 MG/100ML;
TYROSINE 34 MG/GM;
TYROSINE 4.25 MG;
TYROSINE 40 MG;
TYROSINE 40 MG/100ML;
TYROSINE 405 MG/100ML;
TYROSINE 44 MG;
TYROSINE 44 MG/100ML;
TYROSINE 70 MG/100ML;
TYROSINE 95 MG/ML | - 98. Laboratories; Dental Laboratory
- [A commercial laboratory specializing in the construction of dental appliances that conform to a dentist's specifications including the construction of dentures (complete or partial), orthodontic appliances, bridgework, crowns, and inlays. ( HL7V3.0 )] (UMLS (HL7) C1551302) =Manufactured Object; Health Care Related Organization =HealthcareProviderTaxonomyHIPAA;
|
- 49. L-Sarcolysin
- (UMLS (NCI) C0025444) =Amino Acid, Peptide, or Protein; Pharmacologic Substance ;
| - 99. Laboratories; Physiological Laboratory
- [A laboratory that operates independently of a hospital and physician's office to furnish physiological diagnostic services (e.g. EEG's , EKG's, scans, etc.). Facilities offering ONLY physiological services are not certified as independent laboratories. If an independent laboratory offers physiological services IN ADDITION to clinical laboratory services, they are surveyed only for compliance with the clinical laboratory regulations because there are no health and safety regulations for physiological services. ( HL7V3.0 )] (UMLS (HL7) C1551303) =Manufactured Object; Health Care Related Organization =HealthcareProviderTaxonomyHIPAA;
|
- 50. L-tryptophanase
- [also a name for EC 1.13.11.11, TRYPTOPHAN 2,3 DIOXYGENASE, do not confuse. ( CSP )] (UMLS (NCI) C0041260) =Amino Acid, Peptide, or Protein; Enzyme ;
=carbon carbon lyase;
| - 100. Laboratory
- (UMLS (HL7) C1548427) =Idea or Concept =Referral type;
|
home
